Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $76.47M
• Dividend Yield: N/A
• Average Volume (3M): 138.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -99.64%
• EPS Growth: -59.17%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 42,959,170
• 10 Day Avg. Volume: 221,679
• 30 Day Avg. Volume: 138,921
• PEG Ratio: 0.06
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 1.04
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: -0.64
• Enterprise Value/Revenue: -0.92
• Enterprise Value/Gross Profit: -1.27
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $3.00
• Price Target Upside: 74.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.50 ▼(-12.79% Downside)

Repare Therapeutics faces significant financial challenges with consistent losses and revenue volatility, which heavily impacts its overall score. While the technical analysis shows some potential for long-term bullishness, the negative valuation metrics further weigh down the score. The company's strong cash position provides some stability, but the lack of earnings call data and corporate events leaves uncertainties about future prospects.

Positive Factors

Strong Cash Position

A strong cash position provides Repare Therapeutics with the liquidity needed to sustain operations and invest in R&D, crucial for a biotech firm focused on drug development.

Low Debt-to-Equity Ratio

A low Debt-to-Equity ratio suggests financial stability, allowing Repare Therapeutics to focus on long-term growth without the pressure of high debt obligations.

Innovative Product Pipeline

Repare's focus on precision medicine and its innovative pipeline positions it well in the oncology sector, potentially leading to breakthroughs in cancer treatment.

Negative Factors

Revenue Volatility

Significant revenue volatility indicates challenges in achieving consistent financial performance, which can hinder long-term planning and investment.

Consistent Operating Losses

Ongoing operating losses reflect operational inefficiencies and challenge Repare's ability to achieve profitability, impacting its financial health.

Negative Free Cash Flow

Negative free cash flow suggests that Repare is not generating sufficient cash from operations, which may limit its ability to fund new projects or expand its pipeline.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics is a clinical-stage biotechnology company focused on developing precision medicine for patients with cancer. The company specializes in the discovery and development of therapeutics that target DNA damage response mechanisms, leveraging its proprietary platform to identify and advance novel drug candidates. Repare Therapeutics is primarily involved in the oncology sector, aiming to improve treatment outcomes for patients with genetically defined cancers through its innovative product pipeline.

How the Company Makes Money

Repare Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that are interested in co-developing its drug candidates. The company may receive upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of any products that result from these partnerships. Additionally, Repare may engage in strategic licensing agreements, allowing other firms to develop or commercialize its technologies, further contributing to its revenue streams. Research grants and funding from government or non-profit organizations aimed at supporting cancer research may also play a role in its financial model.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics is facing significant financial challenges with consistent losses and revenue volatility. Despite a strong cash position and low leverage, the negative income and cash flow statements highlight operational inefficiencies. The company's liquidity offers some buffer to continue operations and possibly improve in the future.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	53.73M	53.48M	51.13M	131.83M	7.60M	135.00K
Gross Profit	38.71M	40.10M	37.89M	15.11M	-80.25M	-1.65M
EBITDA	-108.21M	-90.22M	-114.27M	-17.82M	-107.19M	-53.41M
Net Income	-109.86M	-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet
Total Assets	130.49M	176.51M	253.90M	364.07M	368.71M	357.09M
Cash, Cash Equivalents and Short-Term Investments	109.47M	152.79M	223.63M	343.94M	341.87M	333.71M
Total Debt	649.00K	1.93M	3.41M	5.43M	7.31M	4.00M
Total Liabilities	20.09M	25.38M	41.82M	84.56M	80.29M	70.26M
Stockholders Equity	110.41M	151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow
Free Cash Flow	-103.34M	-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
Operating Cash Flow	-103.34M	-76.44M	-127.16M	322.00K	-85.80M	-6.08M
Investing Cash Flow	90.87M	49.47M	78.04M	-175.78M	-1.68M	-9.76M
Financing Cash Flow	246.00K	542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.72
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Negative. The current price of 1.72 is below the 20-day moving average (MA) of 1.80, below the 50-day MA of 1.78, and above the 200-day MA of 1.45, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 39.10 is Neutral, neither overbought nor oversold. The STOCH value of 29.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RPTX	47 Neutral	$76.47M	-0.69	-69.96%	―	-99.64%	-59.17%
LTRN	45 Neutral	$39.20M	-2.03	-88.59%	―	―	1.18%
GBIO	41 Neutral	$35.36M	-0.48	-80.81%	―	-17.82%	57.32%
PLRX	37 Underperform	$98.83M	-0.47	-64.27%	―	―	14.19%
PRLD	35 Underperform	$99.61M	-0.99	-96.33%	―	250.00%	15.15%
UNCY	28 Underperform	$78.42M	-1.31	-3987.11%	―	―	66.05%

Repare Therapeutics Corporate Events

Repare Therapeutics’ Promising Study on Advanced Solid Tumors: A Closer Look

Repare Therapeutics Inc. is conducting a Phase 1/1b clinical study titled ‘Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of RP-6306, both as a single agent and in combination with RP-3500 or Debio 0123, in patients with advanced solid tumors. The significance of this study lies in its potential to identify new treatment options for these patients.

Repare Therapeutics Unveils Phase 1 LIONS Trial Data

On October 22, 2025, Repare Therapeutics announced the availability of an abstract related to their Phase 1 LIONS trial of RP-1664. This preliminary data, showcasing the safety and antitumor activity of RP-1664 in advanced solid tumors, will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics Reports Q2 2025 Results and Strategic Moves

Repare Therapeutics Inc. is a clinical-stage precision oncology company that focuses on developing novel therapeutics using its proprietary synthetic lethality approach, targeting genomic instability and DNA damage repair in cancer treatments.

Repare Therapeutics Announces Licensing Deal and Strategic Updates

Repare Therapeutics has entered a worldwide licensing agreement with Debiopharm for its precision oncology drug lunresertib, potentially earning up to $257 million in milestone payments and royalties. The company is also exploring strategic alternatives to enhance shareholder value and expects to report initial data from its LIONS and POLAR trials in Q4 2025, which could significantly impact its market positioning and stakeholder interests.

The most recent analyst rating on (RPTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.